ArticleJournal of pain research2026
Adverse Drug Events Associated with Opioid Treatment for Pain After Motor Vehicle Crash.
Article in Journal of pain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Methodological and Reporting Concerns Regarding "Adverse Drug Events Associated with Opioid Treatment for Pain After Motor Vehicle Crash" [Letter].Journal of pain research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Thousands of motor vehicle crash (MVC) related deaths and injuries occur among older adults every year in the United States. Injuries from MVC may cause acute or chronic pain resulting in functional decline and disability. Opioid treatment poses risk of adverse drug events (ADEs) including dependency, overdose, respiratory problems, and other complications. Our objective was to evaluate the comparative risks of ADEs associated with three opioid prescribing strategies: 1) greater versus lesser days' supply (≥6 days versus ≤5 days), 2) higher versus lower doses (≥30 MME versus <30 MME), and 3) tramadol versus other opioids over 45 days of follow-up. Methods: The study utilized Medicare claims linked to New Jersey drivers' licensing and police-reported crashes to emulate three target trials for each pairwise treatment comparison from May 1, 2007-November 16, 2017. The study included Medicare beneficiaries aged >67 years who initiated opioids within 10 days after MVC. Results: Among 510 beneficiaries, the mean (standard deviation) age was 76.1 (6.6) years, with 59.8% females and 90.4% White race. For the intention-to-treat estimand, risk ratios (RRs) [95% confidence limits (CLs)] were 1.64 (0.64, 4.57), 0.83 (0.45, 1.76), and 0.54 (0.21, 4.01) for days' supply, dose, and tramadol treatment strategies, respectively. There were no significant differences in ADE risk for any of the pairwise treatment comparisons in the intention-to-treat or per-protocol analyses. However, there was a considerable amount of uncertainty surrounding our effect measures. Conclusion: Physicians must continue to exercise caution while considering prescribing opioids for pain management in older adults.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.